UCB welcomes the "Value of Treatment for Brain Disorder" report
Posted by
28-Jun-2017
UCB welcomes the launch of the European Brain Council’s ‘Value of Treatment for Brain Disorders’ report, a comprehensive review of the treatment of neurological diseases across Europe, including conditions such as epilepsy and Parkinson’s disease.
The report describes how inequality still exists between, as well as within, EU Member States, and reveals a clear need to address the equality gap throughout Europe in terms of treatment, detection and intervention. To help address this issue, it is recommended that integrated care and connected health approaches are implemented more widely across healthcare services. The report also makes it clear that improved early intervention, treatment and detection could improve survival rates, reduce complications and disability, improve quality of life and decrease treatment costs.
Interestingly, the report shows that although the Commission has invested €5.3 billion in brain research between 2007 and 2020, this amounts to just over €3 per patient per year. With an ageing population, brain disorders will inevitably become more prevalent and therefore the report calls on the Commission and Member States to do more, and better, before it’s too late.
At UCB we are passionate about creating value for people with epilepsy and Parkinson’s disease, and helping them to live the life they choose.
However, we know that significant issues remain in areas such as diagnosis, access, disease control and social stigma. Whilst epilepsy can be treated very effectively with antiepileptic medication, 30% of patients live with uncontrolled seizures. People with epilepsy might delay or avoid care due to fear, perceived low importance or social stigma. Seizures are also often misdiagnosed, resulting in delayed treatment.
In Parkinson’s disease, non-motor symptoms, such as fatigue and gastrointestinal problems, are missed or misdiagnosed by neurologists in around 60% of consultations, and are often undeclared by patients during consultations, resulting in under-diagnosis and under-treatment.
The ‘Value of Treatment for Brain Disorders’ report aligns with many issues UCB is committed to addressing, including the importance of investing in the research and development of new medicines, and exploring new approaches to managing neurological conditions.
We are working closely with stakeholders across Europe, and across the world, to explore how technology and life sciences can make a real difference by working together across the full spectrum of care - from prevention and prediction, diagnosis and clinical decision making, treatment and self-management as well as recording and reporting outcomes. By blending new technologies with breakthrough medicines, we believe we can dramatically improve outcomes and experience for patients - and we’re committed to being at the forefront of exploring these exciting next generation solutions.
To access the report please click here and follow the conversation online using #BrainTimeMatters and #ValueOfTreatment.
The report describes how inequality still exists between, as well as within, EU Member States, and reveals a clear need to address the equality gap throughout Europe in terms of treatment, detection and intervention. To help address this issue, it is recommended that integrated care and connected health approaches are implemented more widely across healthcare services. The report also makes it clear that improved early intervention, treatment and detection could improve survival rates, reduce complications and disability, improve quality of life and decrease treatment costs.
Interestingly, the report shows that although the Commission has invested €5.3 billion in brain research between 2007 and 2020, this amounts to just over €3 per patient per year. With an ageing population, brain disorders will inevitably become more prevalent and therefore the report calls on the Commission and Member States to do more, and better, before it’s too late.
At UCB we are passionate about creating value for people with epilepsy and Parkinson’s disease, and helping them to live the life they choose.
However, we know that significant issues remain in areas such as diagnosis, access, disease control and social stigma. Whilst epilepsy can be treated very effectively with antiepileptic medication, 30% of patients live with uncontrolled seizures. People with epilepsy might delay or avoid care due to fear, perceived low importance or social stigma. Seizures are also often misdiagnosed, resulting in delayed treatment.
In Parkinson’s disease, non-motor symptoms, such as fatigue and gastrointestinal problems, are missed or misdiagnosed by neurologists in around 60% of consultations, and are often undeclared by patients during consultations, resulting in under-diagnosis and under-treatment.
The ‘Value of Treatment for Brain Disorders’ report aligns with many issues UCB is committed to addressing, including the importance of investing in the research and development of new medicines, and exploring new approaches to managing neurological conditions.
We are working closely with stakeholders across Europe, and across the world, to explore how technology and life sciences can make a real difference by working together across the full spectrum of care - from prevention and prediction, diagnosis and clinical decision making, treatment and self-management as well as recording and reporting outcomes. By blending new technologies with breakthrough medicines, we believe we can dramatically improve outcomes and experience for patients - and we’re committed to being at the forefront of exploring these exciting next generation solutions.
To access the report please click here and follow the conversation online using #BrainTimeMatters and #ValueOfTreatment.
Leave a Comment